25 . 01 .2024
Press release
IMCAS 2024: Galderma to present latest updates from its unparalleled aesthetics portfolio reinforcing its leadership position
22 . 01 .2024
Press release
Galderma announces regulatory approval for Restylane® SHAYPE™, a new hyaluronic acid injectable designed for augmenting the chin region
17 . 01 .2024
Press release
TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously
07 . 12 .2023
News story
Centering patient needs: Dr. Shridharani's shared values with Galderma
30 . 11 .2023
Press release
Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines